ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$14.46 USD
-0.27 (-1.83%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $14.46 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
B Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.46 USD
-0.27 (-1.83%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $14.46 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
B Value A Growth B Momentum A VGM
Zacks News
Acadia (ACAD) Up More Than 20% in Past 3 Months: Here's Why
by Zacks Equity Research
Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, has seen strong uptake so far. Its label expansion studies also hold promise.
Acadia (ACAD) Partners With Stoke for CNS Disorder Therapies
by Zacks Equity Research
Acadia (ACAD) signs a collaboration agreement with Stoke Therapeutics to develop/commercialize RNA-based medicines for addressing genetic neurodevelopmental diseases.
ACADIA (ACAD) Up on Resubmission Plan for Nuplazid sNDA to FDA
by Zacks Equity Research
ACADIA (ACAD) to resubmit sNDA for Nuplazid (pimavanserin) to the FDA for treating hallucinations and delusions associated with dementia focused on Alzheimer's disease psychosis. Shares rise.
Biotech Stock Roundup: ACAD Up on Study Results, BHVN's Pipeline Update & More
by Ekta Bagri
Acadia's (ACAD) study results and other pipeline updates have been the biotech sector's few key highlights during the past week.
ACADIA's (ACAD) Rett Syndrome Candidate Meets Goal in Study
by Zacks Equity Research
ACADIA's (ACAD) phase III study, evaluating the efficacy and safety of trofinetide in patients with Rett syndrome, meets co-primary endpoints. Shares rise.
ACADIA's (ACAD) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
ACADIA Pharmaceuticals (ACAD) posts narrower-than-expected loss for the third quarter of 2021. Revenues also beat estimates. Resultantly, its shares rise in after-hours trading.
Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of 66.67% and 3.32%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Should Schwab U.S. MidCap ETF (SCHM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHM
Humana (HUM) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Humana's (HUM) third-quarter earnings are expected to have gained from higher revenues and a solid contribution from its Retail and Healthcare Services segments.
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dynavax (DVAX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Dynavax's (DVAX) topline comprising sales of hepatitis B vaccine Heplisav-B, vaccine adjuvant CpG 1018 and other revenues is expected to retain the growth momentum in Q3 results.
4 Healthcare Stocks to Top Q3 Estimates Amid Coronavirus Woes
by Srijita Guha
Factors like an aging populace and demand for products and services are likely to reflect on the Q3 results of ACAD, MD, ACHC and VRTX.
Acadia (ACAD) Down 10.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ACADIA (ACAD) Q2 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
ACADIA's (ACAD) loss narrows in the second quarter of 2021 while its revenues miss the mark. The company has reduced its revenue guidance for 2021. Shares down in after-hours trading.
Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of 10.00% and -9.27%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cassava Sciences (SAVA) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Investors will be keen on updates from on its lead candidate, sumifilam, for Alzheimer's disease when Cassava (SAVA) reports Q2 results.
Synlogic's (SYBX) Begins Phase I Study for PKU Treatment
by Zacks Equity Research
Synlogic (SYBX) initiates phase I study of SYNB1934, a synthetic biotic candidate to treat PKU. The drug is an evolved strain of SYNB1618, another PKU candidate currently undergoing phase II study.
AcelRx (ACRX) Inks Agreement With Aguettant for Dzuveo in Europe
by Zacks Equity Research
AcelRx (ACRX) enters a licensing agreement for Dzuveo in Europe and an in-licensing agreement for two products in the United States.
Bear of the Day: Inovio Pharmaceuticals (INO)
by Madeleine Johnson
Is it too late to buy this coronavirus vaccine stock?
Why Is Acadia (ACAD) Up 11.3% Since Last Earnings Report?
by Zacks Equity Research
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's How Much You'd Have If You Invested $1000 in Acadia Pharmaceuticals a Decade Ago
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
ACADIA (ACAD) Q1 Earnings Beat, Revenues Fall Shy of Estimates
by Zacks Equity Research
ACADIA's (ACAD) loss narrows in the first quarter of 2021 while its revenues miss the mark. Robust Nuplazid performance drives the top line year over year.
Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of 20.75% and -5.63%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.